NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company focused on developing nanomaterials for antiviral therapy, announced that independent analyst Robert LeBoyer of Noble Capital Markets has initiated research coverage with an “Outperform” rating and a $6.00 price target. The report reviews the company’s lead programs, including its broad-spectrum antiviral candidate NV-387, along with longer-term development initiatives. NanoViricides noted that while it provided publicly available information and answered technical questions, the analyst independently developed all estimates, financial models and projections.
The initiation of coverage by Noble Capital Markets is significant for investors as it provides an independent assessment of NanoViricides’ potential. The $6 price target suggests substantial upside from current levels, reflecting confidence in the company’s antiviral technology platform. This rating could attract more attention from the investment community and potentially increase liquidity for the stock.
Separately, President and Executive Chairman Anil R. Diwan participated in a “Fireside Chat” published by StockInvestor Daily’s IPO-Edge program. During the chat, Diwan discussed NanoViricides’ antiviral technology platform, the potential of NV-387 against multiple viral diseases and variants, the company’s regulatory progress including FDA Orphan Drug Designation and its Rare Pediatric Disease Designation filing for measles, as well as the resurgence of infectious diseases such as measles, mpox, and Ebola.
The company’s lead drug candidate, NV-387, is a broad-spectrum antiviral drug being developed for the treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections and Measles. The company is currently focused on advancing NV-387 into Phase II human clinical trials. Additionally, the company has developed NV-CoV-2 (API NV-387) for COVID-19 and NV-CoV-2-R, which encapsulates remdesivir.
NanoViricides’ platform technology is based on the TheraCour nanomedicine technology, licensed from TheraCour Pharma, Inc. The company holds a worldwide exclusive perpetual license for several drugs targeting specific mechanisms for the treatment of various human viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes, Influenza, Dengue, Japanese Encephalitis, West Nile, Ebola/Marburg, and certain Coronaviruses.
The company also highlighted its regulatory progress, including an FDA Orphan Drug Designation and a Rare Pediatric Disease Designation filing for measles. These designations can provide incentives for drug development, such as tax credits and market exclusivity, potentially accelerating the path to approval.
For more information about NanoViricides, visit www.nanoviricides.com. To view the full press release, visit https://ibn.fm/7XBbY.
